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Abstract: Highly active antiretroviral therapy (HAART) has dramatically improved the 
prognosis of patients with HIV. Low adherence and toxicity among HIV-positive patients starting 
HAART, however, can lead to discontinuation of therapy and limit long-term treatment success. 
Moreover, increasing prevalence of primary resistance (>10%) as well as the accumulation of 
mutations resulting from continued selection pressure exerted by ongoing antiretroviral treatment 
in patients failing virologically, mean that new compounds are needed that retain antiretroviral 
activity against resistant strains. Tipranavir (Aptivus®) is a novel protease inhibitor (NPPI), which 
is characterized by a unique genetic resistance proﬁ  le that allows it to remain active against 
HIV strains resistant to currently licensed protease inhibitors (PIs). Tipranavir was approved 
and licensed in the US and Europe in 2005 for treatment-experienced patients. This review 
summarizes the currently available data and studies on tipranavir and discusses the possible 
position of tipranavir in the currently available armamentarium of antiretroviral drugs.
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Introduction
Substantial improvements in HIV/AIDS-associated morbidity and mortality has been 
achieved, since highly active antiretroviral therapy (HAART) was introduced in the 
mid-1990s (Carpenter et al 2000; Jones et al 1999; Palella et al 1998). However, despite 
these achievements, an increasing population of patients harbour HIV strains resistant 
against at least one class of antiretroviral agents (Little et al 2002). Of a representative 
sample from 83,475 patients in the US taking antiretroviral (ARV) therapy, 76% had 
plasma viral loads greater than 500 copies/mL, and were resistant to at least one drug; 
48% were infected with HIV that was resistant to two ARV drug classes (Richman et al 
2004). Furthermore, in a further study up to 50% of patients were reported to have failed 
their initial antiretroviral regimen after a median duration of only 1.6 years (Bartlett 
et al 2001; Chen et al 2003). However, recent data suggest that with the availability of 
boosted protease inhibitors (PIs) and non-nucleoside reverse transcriptase inhibitors 
(NNRTIs), with improved pharmacokinetic proﬁ  les and increasing forgiveness of the 
regimens, the percentage of patients developing virological failure under ﬁ  rst-line 
ARV therapy is declining substantially (Lampe et al 2005).
Moreover, another important issue in resistance development is the increasing 
number of new primary multi-drug resistant HIV infections which in some areas like 
New York (USA) already exceeds 3.8% (Clavel and Hance 2004; Markowitz et al 
2005; Boden et al 1999).
The emergence of ARV drug resistance reduces the ability of current agents to control 
viral replication and to construct effective ARV regimens for patients who are failing 
their treatment regimens. Evidently, with each drug failure the number of alternative 
agents that are active against the resistant virus becomes more limited (Montaner 2003; 
Yeni et al 2004) and therefore the need for new potent drugs is obviously growing with Therapeutics and Clinical Risk Management 2007:3(4) 642
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the development of (multidrug-)resistant strains and it is 
necessary to provide new treatment options for patients with 
resistant viral isolates (Montaner 2003).
Tipranavir (Aptivus®, Boehringer Ingelheim) (TPV) was 
licensed and approved in June and October 2005 in the US 
and Europe, respectively. TPV is a novel protease inhibitor 
which is highly selective for therapeutic intervention in the 
viral life cycle by blocking the HIV-1 and HIV-2 protease 
(Thaisrivongs and Strohbach 1999). Importantly, TPV has a 
unique resistance proﬁ  le which is characterized by sufﬁ  cient 
antiviral activity in vitro against viral strains cross-resistant 
to other marketed protease inhibitors (Larder et al 2000). 
This property makes the drug interesting for treatment of 
patients who are PI-experienced or who are infected with 
PI-resistant viral isolates.
Dosage of    TPV
A self-emulsifying drug delivery system (SEDDS), contains 
250 mg TPV free acid in a soft gel TPV capsule. Dosage for 
treatment-experienced patients is recommended at 500 mg 
twice daily taken with a meal, as deﬁ  ned in the pre-clinical 
Phase IIb dose optimization study (BI 1182.52) performed in 
216 treatment-experienced patients (Gathe et al 2003). TPV, 
as other PIs, must be co-administered with ritonavir (RTV) 
to enhance plasma levels; a RTV dose of 200 mg bid is rec-
ommended. In study 1182.52, patients replaced their failing 
PI for TPV/r administered at 3 different doses for 2 weeks 
and subsequently changed their background regimens and 
were followed for a total of 24 weeks. Patients who were 
taking 500/200 mg TPV/r, showed similar antiviral activity 
compared with patients treated with 750/200 mg TPV/r, 
although the latter group experienced 10% more frequent 
(severe) adverse events after 24 weeks. In addition, one arm 
was treated with 500 mg TPV and a boosting dosage of RTV 
100 mg bid, as commonly used for other PIs. Even though 
patients achieved a pVL reduction of more than 0.5 log10 after 
2 weeks, the viral load reduction could not be sustained after 
24 weeks. Thus, the daily pill burden for TPV/r is eight pills, 
which is higher than for the other currently licensed PIs. In 
addition the use of TPV/r in a once-daily regimen has not 
been investigated and is thus not available at present.
Resistance proﬁ  le of tipranavir
In vitro data has shown, that primary TPV resistance develops 
slowly and involves the acquisition of several speciﬁ  c protease 
gene mutations (Doyon et al 2005). These results demonstrate 
that in vitro up to 10 mutations are involved in the develop-
ment of resistance to TPV: L10F, I13V, V32I, L33F, M36I, 
K45I, I54V, A71V, V82L, and I84V. All of these mutations 
have previously been described in the presence of other PIs 
except for the active site mutation V82L which seems to be 
unique to TPV (Johnson et al 2005). HIV protease mutation of 
Val82 to Ala, Phe, Thr, or Ser has previously been implicated 
in resistance to PIs. However, this is the ﬁ  rst description of 
a Leu substitution at the V82 position (Johnson et al 2005). 
Interestingly, an initial TPV resistance study identiﬁ  ed V82L 
in the protease of emerging viruses, but investigators were 
unable to reconstitute a resistance phenotype by reintroduc-
ing this mutation into a wild type background (Kemp et al 
2000). This study conﬁ  rmed that V82L alone does not confer 
resistance to TPV, but contributes to a 2.4-fold increase in 
resistance when selected for on a background of ﬁ  ve pre-
existing protease mutations. These results also highlight the 
requirement for the presence of six speciﬁ  c mutations in the 
protease (I13V, V32I, L33F, K45I, V82L, I84V), and three in 
the active site of the enzyme to confer >10-fold resistance 
to TPV. Therefore, it suggests that although the majority of 
mutations selected by this PI do not signiﬁ  cantly differ from 
those selected by other PIs, the genetic barrier for the develop-
ment of resistance to TPV is higher than for most other PIs. 
This could explain why TPV has such a broad activity against 
PI resistant clinical isolates.
To determine the relationship between protease mutations 
detected in genotype to phenotypic susceptibility and viro-
logic response to TPV a series of regression analyses were 
performed using the TPV program Phase II data. Validation 
included analyses of Phase III study datasets to determine 
if the same mutations would be selected and to assess how 
these mutations contribute to multiple regression models of 
tipranavir phenotype and of virologic response. A string of 16 
protease positions and 21 mutations were identiﬁ  ed : 10V, 13V, 
20M/R/V, 33F, 35G, 36I, 43T, 46L, 47V, 54A/M/V, 58E, 69K, 
74P, 82L/T, 83D, and 84V. An increasing number of muta-
tions (>8 TPV associated mutations) at these positions were 
associated with reduced phenotypic susceptibility and blunted 
virologic responses to TPV. Lower TPV scores and the use of 
active drugs, especially of a new class, were associated with 
improved responses to a TPV-containing regimen.
In addition, TPV shows considerable efﬁ  cacy in the 
presence of universal protease inhibitor resistance associated 
mutations (PRAMs) like L33I/V/F, V82A/F/L/T, I84V and 
L90M, which are mutations conferring resistance against all 
currently available PIs. This robust activity against protease 
inhibitor (PI-) resistant strains still remains unexplained, 
although some authors have speculated that TPV has a 
broader molecular ﬂ  exibility, which allows it to ﬁ  t into the Therapeutics and Clinical Risk Management 2007:3(4) 643
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active pocket of the protease enzyme (Larder et al 2000). 
Other mutations, outside the active site (secondary muta-
tions), can increase resistance in the presence of major   pri-
mary mutations like L10I/V, K20M/L/T, and I54V, as well as 
additional primary mutations such as M46I, and V82A/F/L/T. 
However, even the activity of TPV is not unlimited; despite 
good short term activity and a >1.0 log viral load reduction 
after 2 weeks in patients whose isolates carried 3 or more 
PRAMs, the susceptibility to TPV begins to decrease at this 
level of protease resistance, probably in part, due to the lack 
of active drugs to support TPV’s activity.
It is important to point out that the resistant strains which 
can emerge under a “classic” PI-based regimen differ slightly 
from those that emerge under a TPV based regimen. This 
means that a failure of a TPV-containing regimen does not 
necessarily imply that the virus has become resistant to all 
other PIs. However, in vitro data suggests that TPV/r resis-
tant viral strains, which developed from wild-type HIV-1, 
exhibited a 2 to 154 fold decrease in susceptibility to the PIs 
amprenavir, indinavir, lopinavir, nelﬁ  navir and ritonavir, but 
still remained sensitive to saquinavir (Doyon et al 2005).
This is most probably attributable to the fact that TPV 
failed to select for the SQV primary mutations G48V and 
L90M in these studies (Johnson et al 2005; Jacobsen et al 
1995). Characterization of human cross-resistance was most 
signiﬁ  cant for ATV and RTV, and in vitro resistance for these 
was previously reported to be associated with mutations at 
positions V32I/L33F/A71V/I84V (ATV) (Gong et al 2000) 
and V82F/I84V (RTV) (Markowitz et al 1995).
Efﬁ  cacy and antiviral activity
TPV appears to have antiviral activity against most viral iso-
lates with PI resistance (Larder et al 2000; Back et al 2000; 
Poppe et al 1997; Rusconi et al 2000; Schwartz et al 2002). 
In a highly active antiretroviral therapy regimen, especially 
in chronic HIV-1 infected patients with multiple resistant 
isolates, it is often difﬁ  cult to discern the effects of a single 
drug. To be able to draw direct conclusions for the efﬁ  cacy of 
a single drug, it is therefore important to obtain monotherapy 
data, which can be extracted from several studies. In the above 
cited dose ﬁ  nding study BI 1182.52 (n = 216) the failing PI 
was discontinued and replaced by TPV/r for two weeks with 
no adjustment changes in the backbone regimen. In this 
context TPV/r was considered a functional monotherapy. 
After two weeks, an optimized backbone regimen (OBR) 
was added based on genotypic testing and patients were 
switched to the OBR + TPV/r. In the intent to treat analysis 
(last observation carried forward [LOCF]) the median plasma 
viral load (pVLs) decreased by 0.87–1.18 log10 copies/mL 
during the ﬁ  rst two weeks of TPV/r functional monotherapy 
(Gathe et al 2003). Similar reductions were obtained when 
treatment-naïve patients (n = 31) received TPV or TPV/r 
monotherapy in different dosages for 14 days (McCallister 
et al 2004). At day 15 the median decreases in pVL were 
signiﬁ  cantly greater in the two RTV-boosted arms with a 
decline of −1.43 log10 copies/mL and −1.64 log10 copies/mL 
compared to the unboosted TPV arm treated with 1200 mg 
BID (old formulation of TPV), in which the patients had only 
a pVL reduction of 0.77 log10 copies/mL. This reduction was 
too low to keep a sustainable plasma viral load reduction as 
it has been shown for different ARVs that a decrease of pVL 
of less than 0.75 log10 copies/mL already at day 6 indicates 
a poor long-term response in 99% of the patients (Polis et al 
2001). Whether lower doses of TPV/r than the one currently 
approved can exert signiﬁ  cant antiviral activity in patients 
with less resistant isolates remains to be determined.
Efﬁ  cacy data of the Phase III trials: 
RESIST -1 and RESIST -2
The TPV Phase III program studied treatment-experienced 
patients with proven viral resistance in two large, 
multi-national, controlled, pivotal trials (RESIST-1 and 
RESIST-2 -Randomized Evaluation of Strategic Interven-
tion in Multi-Drug ReSistant Patient with Tipranavir) 
(Hicks et al 2006). RESIST-1, performed in the United 
States, Canada and Australia and RESIST-2, performed in 19 
countries of Europe and Latin America, were Phase III safety 
and efﬁ  cacy trials in 620 (RESIST-1) and 863 (RESIST-2) 
HIV- positive adults with three-class ARV experience, who 
had failed at least two PI-based regimens, and whose isolates 
had no more than two protease mutations at position 33, 82, 
84 or 90. This outline was employed based on the assump-
tion that patients with three or more mutations at these key 
positions were less likely to respond to any PI-based regimen, 
including TPV/r.
Both trials examined the treatment response up to 48 weeks 
of TPV/r versus a comparator (control) group (CPI) in which 
patients received one of several marketed RTV-boosted PIs. 
Before randomization, investigators selected a comparator PI 
(among lopinavir, indinavir, saquinavir, and amprenavir) that 
offered patients the best opportunity for treatment response 
and an optimized background regimen based on treatment his-
tory and resistance testing. The use of enfuvirtide (ENF) was 
permitted in both arms, but had to be chosen before randomiza-
tion. Following the 1:1 randomization, patients could be treated 
with any of four RTV-boosted comparator PIs or TPV/r along Therapeutics and Clinical Risk Management 2007:3(4) 644
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Table 1 Baseline demographic data of the RESIST studies I and II
Total treated  582    577 
Median Age (years [range])  43.0   [17-80]  43.0  [21-72]
Gender (male, N[%])  503  [86.4]  516  [89.4]
Race (Ewhite, N [%])  430  [73,9]  414  [71.8]
Median baseline HIV-1 RNA   4.83  [2.34–6.52]  4.82  [2.01–6.76]
(log10 copies/ml [range])
Patients stratiﬁ  ed by        
baseline viral load (N [%])
10,000 copies/ml  91  [15.6]  90  [15.6]
>10,000–100,000 copies/ml  259  [44.5]  253  [43.8]
>100,000 copies/ml  232  [39.9]  234  [40.6]
Median baseline   155  [1–1893]  158  [1–1184]
CD4 + cell count (cells/µl
[range])
Patients stratiﬁ  ed by baseline        
CD4 + count (N [%])
350 cells/µl  87  [14.9]  99  [17.2]
201–350 cells/µl 133  [22.9]  134  [23.2]
50–200 cells/µl 226  [38.8]  193  [33.4]
<50 cells/µl 133  [22.9]  148  [25.6]
with an optimized non-PI ARV backbone regimen. Patients 
in these trials were highly treatment-experienced (median 
use of 12 ARV before randomization) and the majority were 
most likely resistant to the comparator PI chosen. The median 
baseline viral load and CD4+ count were 4.82 log10 copies/mL 
and 155 cells/µl, respectively.
A total of 1483 patients were randomized and treated in 
RESIST-1 and -2. At week 24, data of 1159 patients was 
available for analysis. The two treatment arms were well 
matched in demographics and disease baseline characteristics 
(see Table 1 for baseline characteristics). Patients had taken a 
median of 12 ARV drugs before enrolment: six NRTIs, one 
NNRTI and four PIs. Twelve percent of the patients had taken 
enfuvirtide previously. In RESIST-1 the most frequently 
chosen comparator PI was lopinavir/r but was amprenavir/r 
in RESIST-2. However based on genotypic data, the virus 
was already resistant to the pre-selected PI in 66.7% of the 
patients in the comparator group.
In the combined analysis of these two studies, the mean 
plasma viral load reduction was 1.2 log10 copies/ml in the 
TPV/r arm and 0.6 log10 copies/mL in the comparator arm at 
week 24. This response was maintained at week 48 and the 
mean change in VL was a reduction of −1.14 log10 copies/mL 
in patients taking TPV/r and only −0.54 log10 copies/mL in the 
control arm at this time point. The maximal pVL reduction oc-
curred at week 4 in the TPV/r arm and at week 2 in the control 
group. Achieving an undetectable viral load (<50 cop/mL) in 
these treatment-experienced populations was difﬁ  cult, taking 
into account the extensive antiretroviral pre-treatment of the 
study subjects. Only 23.9% of the patients in the TPV/r and 
9.4% in the control group were fully suppressed after being 
administered the prescribed chemotherapeutic regimens at 
week 24 (p < 0.001). Similar to what has been seen in other 
studies, patients with lower pVL and higher CD4+ counts at 
baseline responded better to therapy than those with more ad-
vanced disease (van Leth et al 2004; Clotet et al 2004). Patients 
with 2 or 3 previously used PIs, who were more likely to have 
additional ARV drugs to use as background regimens, had a 
greater decrease in viral load than more experienced patients 
and therefore were more likely to achieve a fully suppressed 
viral load. Also the additional use of enfuvirtide (ENF) was 
associated with a better outcome for both groups; 58.2% of the 
patients taking TPV/r plus ENF achieved a treatment response, 
deﬁ  ned as VL reduction 1.0 log10 copies/mL, compared 
to 25.8% of patients in the control group + ENF (Figure 1) 
(Cooper et al 2005). This observation was similar to other 
studies, that patients taking regimens containing additional, 
active ARV drugs, experienced a substantially higher decrease 
in viral load and increase in CD4+ counts compared to those 
who had no more additional active drugs available.
At week 48 patients taking TPV/r were twice as likely to 
experience a treatment response as those in the control group. 
The treatment response (TR) rate was 33.6% (251/746) in 
the TPV/r arm and 15.3% (113/737) in the comparator arm 
(p < 0.001). More than 80% of patients who achieved a treat-
ment response had week 48 plasma viral loads below 400 c/mL. 
The TR was 48.5% (82/169) in patients who took TPV/r plus 
an optimized background regimen (OBR) that contained at least 
one active ARV, eg, ENF, but it was 20.0% (27/135) in patients 
who took CPI/r plus ENF. Patients taking TPV/r were more 
likely to achieve a durable response than control patients.
In one sub-analysis the treatment response rate of each single 
comparator PI was stratiﬁ  ed and compared to the treatment 
response rate of TPV/r at week 24. This analysis showed that 
the treatment response rates for each single comparator PIs were 
lower than the response rate for TPV/r. In detail, the treatment 
response rates were 39.6% for TPV/r, 21.4% for LPV/r, 15.3% 
for SQV/r and 18.8% for APV/r. However, comparing the TPV/r 
group to a LPV/r inexperienced group in a sub-interim analysis, 
the difference in virologic response in both groups was not 
statistically signiﬁ  cant (Cooper et al 2005) (see Figure 2).
In a 48-week analysis, the median time to treatment 
failure (TTF) was 113 days in the overall TPV/r group and 
0 days in the CPI/r group (p < 0.0001). The median TTF 
was 0 days in the control group because <50% of the con-
trol patients achieved a virologic response in the RESIST 
studies, even though they were taking a standard of care Therapeutics and Clinical Risk Management 2007:3(4) 645
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PI/r plus an OBR. Patients randomized to the TPV/r arm 
had a 37% lower probability of treatment failure than those 
randomized to a CPI/r (HR = 0.63, p < 0.0001).
Including an active ARV in the OBR, such as ENF, 
increased the median TTF to 337 days in the TPV/r arm but 
the TTF was unchanged in the CPI/r arm in patients who took 
ENF (0 days) (p < 0.0001) (Cahn et al 2005).
As for the viral load reduction the CD4+ count increase 
was signiﬁ  cantly different in the TPV/r arm and the com-
parator arm. By week 24, the median CD4+ cell count had 
risen by 34 cells/µl in the TPV/r and only by 4 cells/µl in the 
control group. At 48 weeks, only the mean CD4+ cell count 
is published and therefore unrivalled to the 24 week data. 
The mean CD4+ T cell count rose by 45 cells/µl in the TPV/r 
Figure 1 Effect of T20 (ENF) on Treatment Response in the TPV/r compared to the CPI/r Arms.
Figure 2 Comparison of Efﬁ  cacy of TPV/r and LPV/r in LPV stratum (data from the RESIST interim analysis).
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arm and only by 21 cells/µl in the control group by week 48 
(Cooper et al 2005; Cahn et al 2005).
As the participation in the RESIST-1 and -2 studies was 
restricted for those patients infected with virus that car-
ried three or more mutations at codons 33, 82, 84 and 90 
(PRAMs), they were eligible to be enrolled in the study BI 
1182.51. Enrolled were 315 HIV-1 infected, triple ARV-class 
experienced patients, who had at least received two PI based 
ARV regimens and a pVL of above 1000 log10 copies/mL 
at the study entry. The patients were randomized to receive 
one of the bid regimens containing either LPV/r + OBR, 
APV/r + OBR, SQV/r + OBR or TPV/r + OBR. During 
the ﬁ  rst two weeks of administration of TPV/r the median 
pVL reduction from baseline was −1.06 log10 copies/mL 
(Figure 3). By contrast, the median reduction in the other 
treatment arms was lower and ranged from a decline of −0.15 
to −0.38 log10 copies/mL (Leith et al 2004). When TPV/r 
was added to the other single PI regimen, there was a further 
reduction in median pVL in all three PI arms by −0.96–1.19 
log10 copies/mL. Subsequently, however, virological rebound 
was noticed in all study arms (Boehringer Ingelheim GmbH 
International 2005). This trend towards baseline pVLs in all 
treatment arms may be accounted for a lack of a sufﬁ  cient 
OBR, which suggests that not enough additional, active 
drugs were part of the new regimen to support the antiviral 
activity of TPV/r. This data underlines the need to construct 
a TPV/r-based HAART regimen similar to the other PIs, 
with as many active drugs as possible in order to achieve a 
durable response.
Side effects
At 24 weeks, adverse events and side effects associated with 
TPV/r are commonly gastrointestinal, such as diarrhoea 
(10.9%), nausea (6.7%), vomiting (3.4%), and abdominal 
pain (2.8%) (Cahn et al 2005; Pierone et al 2005; Hicks 2004). 
Other adverse events reported in the studies were pyrexia 
(4.6%), headache (3.1%), bronchitis (2.9%), depression (2%), 
rash (2%) asthenia and fatigue (4%). As tipranavir is a sulfa-
containing (2-Pyridinesulfonamide) drug, it should be used 
with caution in patients with a known sulfa allergy, although a 
ﬁ  nal association has not been proven. Mild to moderate rashes 
including urticarial rash, maculopapular rash, and possible 
photosensitivity have been reported in subjects receiving TPV. 
In Phase 2 and 3 trials, rash was observed in 14% of females 
and in 8–10% of males receiving TPV/r (GmbH B.I. 2004). 
Overall the majority of the reported side effects were mild or 
moderately intense and comparable with the other boosted 
PIs. The most common side effects observed in RESIST-1 
and RESIST-2 are summarized in Table 2.
The long-term effects of tipranavir are clearly presently 
unknown. In a 4-year follow-up study of treatment experi-
enced patients, TPV/r therapy was well tolerated, adverse 
Figure 3 BI 1182.51 study.
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events were not associated with treatment discontinuation, 
and no new adverse event emerged after long-term follow-
up (Pierone et al 2005). Recently, however, Boehringer 
Ingelheim has distributed information on 14 reports of fatal 
and non-fatal intracranial hemorrhage in the APTIVUS 
clinical development programme. These have occurred 
in 13 out of 6,840 HIV-1 infected individuals receiving 
APTIVUS/r in clinical trials, which corresponds to a rate of 
0.2/100 patient exposure years (PEY). A literature review of 
ICH in HIV-infected individuals found that the rate of ICH 
observed in AIDS patients not receiving combination antiret-
roviral therapy is the same (0.2/100 PEY) as reported in the 
APTIVUS clinical trials. Notably this rate is approximately 
25-fold higher than the rate in non-HIV-infected persons. 
Therefore, the clinical impact of these ﬁ  ndings still needs 
to be determined.
Some laboratory abnormalities are potentially important 
and should be monitored closely. In patients enrolled in the 
RESIST studies taking ritonavir boosted tipranavir, 45.1% 
showed elevated triglycerides, 17.5% elevated liver enzymes 
(esp. γ-GT and AST) and 14.6% elevated cholesterol at 
week 24 (% ﬁ  gures refer to all severity Grades {1–4}). 
Table 3 summarises the grade 3 and 4 laboratory abnormali-
ties recorded in the RESIST trials. The proportion of patients 
who experienced a Grade 3 or 4 adverse event in elevated 
liver enzymes were 6.9% in RESIST-1 versus 1.3% in the 
CPI arm and 5.2% in RESIST-2 vs 2.2% in the CPI group. 
Similarly, the Grade 3/4 cholesterol elevations were higher in 
the TPV/r arm with 3.3% vs 0.3%, as well as the Grade 3/4 
triglyceride levels with 21% vs 11.3% in the control group. 
Other reported laboratory abnormalities, more frequently 
observed, were decreased white blood cell count (3.6%) and 
elevated amylase (2.9%) during this study, which however 
were lower than in the comparator PI-arm.
Tipranavir is contraindicated in patients with moderate 
and severe hepatic impairment (Child-Pugh Class B and 
C) and should be used with caution in patients with known 
hepatitis B or C. TPV has been associated with hepatitis and 
signiﬁ  cant liver damage (hepatic decompensation), including 
some fatal cases (Pierone et al 2005). Therefore liver function 
tests should be performed prior to starting treatment with 
TPV and rechecked regularly throughout the duration of 
treatment. Further subanalyses in the RESIST studies were 
performed in patients with hepatitis coinfection upon inclu-
sion in the study. Overall 49 patients in the TPV/r arms and 
68 patients in the control arms had an HCV infection in the 
RESIST-1/2 studies; 26 (TPV/r) and 42 (CPI) were infected 
with HBV. The types and frequencies of AEs were compa-
rable in hepatitis negative and hepatitis co-infected patients, 
whereas no hepatic events occurred in 5% of either hepatitis 
negative or hepatitis co-infected TPV/r patients. The frequen-
cies of hepatobiliary events were similar in hepatitis negative 
and hepatitis co-infected patients. The antiviral activity of 
TPV was not affected by HCV or HBV co-infection. Patients 
with HCV or HBV co-infection however, are at an increased 
risk for developing transaminase elevations and, therefore 
a close monitoring of liver parameters is necessary in these 
patients (Rockstroh et al 2005).
A total of 3/75 (4%) patients who died while on or 
after taking TPV/r were considered treatment-related in the 
RESIST studies. Two of these three patients had severely 
complicated end-stage AIDS and a deﬁ  nite reason for death 
Table 2 Adverse events (AEs) in RESIST and RESIST 2 trials
Adverse events  TPV/r + OBR   CPI/r + OBR
  (n = 746) [%]  (n = 737) [%]
Gastrointestinal Disorders  46.8  42.6
 Diarrhoea  13.4  11.1
 Nausea  11.7  7.9
 Vomiting  3.8  2.8
 Flatulence  2.9  1.9
 Abdominal  disentsion  2.5  1.8
 Abdominal  pain  2.4  2.7
 Loose  stools  1.6  1.2
 Dyspepsia  1.1  0.7
Metabolism and Nutrition Disorders   
 Anorexia  1.1  0.9
 Hypertriglyeridaemia  1.9  0.8
 Hyperlipidaemia  1.2  0.4
  General Disorders   
 Fatigue  4.4  2.6
  Nervous System Disorders   
 Headache  3.5  1.2
Skin Disorders   
 Rash  1.6  0.9
 Puritus  1.1  0.4
Table 3 Grade 3 and 4 laboratory events in Resist-1 and Resist-2 
(week 24 data)*
  TPV/r + OBR  CPI/r + OBR
  (n = 732) [%]  (n = 726) [%]
Haematology  
  WBC count decrease  3.5  5.5
Chemistry  
 ALT  5.9  1.8
 AST  4.0  1.7
 Amylase  4.5  5.9
 Cholesterol  3.3  0.3
 Triglycerides  21.0  11.3
*reported in = 2% of patientsTherapeutics and Clinical Risk Management 2007:3(4) 648
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could not be stated by the investigator. One of these patients 
died as a result of multi-system organ failure including 
hepatic failure with hyperbilirubinemia. The third patient 
did not have end-stage AIDS and was taking TPV/r with 
ddI, d4T, NVP as a backbone. He was hospitalized with 
severe lactic acidosis and elevated hepatic transaminases, 
subsequently developing respiratory failure and brain stem 
infarction (Boehringer Ingelheim GmbH International 2005; 
2004 unpublished data, Boehringer Ingelheim GmbH). This 
case of hepatotoxicity was most likely due to mitochondrial 
toxicity deriving from the d4T/ddI combination inducing 
hepatic steatosis and lactic acidosis.
Drug-drug interactions
As tipranavir is being metabolized through the CYP3A4 
system in the endoplasmatic reticulum of the liver, the 
concurrent use of medications using the same metabolism 
pathway may induce signiﬁ  cant drug-drug interactions. Drugs 
such as HMG-CoA reductase inhibitors or warfarin can 
lead to substantial increases in plasma concentrations (2005 
Boehringer Ingelheim International GmbH; Boehringer 
Ingelheim Pharmaceuticals Inc 2005; Boffito 2006). 
Indeed the product label states that co-administration of 
TPV and 200 mg of RTV with lovastatin or simvastatin 
is not recommended. Pravastatin and atorvastatin however 
can be co-administered. With regard to atorvastatin the 
recommendation is given to start with the lowest dose 
possible and to perform careful monitoring. Patients receiving 
concomitant warfarin therapy should receive frequent INR 
(international normalized ratio) monitoring upon initiation 
of TPV/r therapy. Rifampin, St. John’s Wort (Hypericum 
perforIatum) and delavirdine have been demonstrated to 
lower the levels of TPV by 80% with the risk of diminished 
plasma concentration and consequent reduced antiviral 
effects (Boehringer Ingelheim GmbH International 2005; 
2005 Boehringer Ingelheim International GmbH; Boehringer 
Ingelheim Pharmaceuticals Inc 2005). Additionally, as it 
has been shown for atazanavir or fos-amprenavir, antacids 
partially lower the plasma levels of TPV with an AUC 
reduction of 25–30% and Cmax by 25–30% (Bofﬁ  to 2006; 
Van Heeswijk et al 2004). Table 4 summarises some of the 
main drugs which should not be co-administered with TPV/r 
or have signiﬁ  cant potential for drug-drug interactions.
It is important to highlight that TPV may have an effect 
on the plasma levels of other antiretroviral drugs and dose 
adjustment has not been established yet (2005 Boehringer 
Ingelheim International GmbH; Boehringer Ingelheim Phar-
maceuticals Inc 2005; Bofﬁ  to 2006). The addition of TPV/r 
did not change the pharmacokinetics of stavudine (d4T), 
lamivudine (3TC), efavirenz (EFV), enfuvirtide (ENF) or 
nevirapine (NVP) and therefore no adjustment in dosage 
was required when they were co-administered with TPV/r. 
However, as seen with other RTV boosted PIs, the exposures 
to abacavir (ABC) and zidovudine (AZT) were both signiﬁ  -
cantly decreased by 35% and 40% of the recommended area 
under the curve (AUC) dosage at steady state, although the 
clinical signiﬁ  cance of these ﬁ  ndings still remains undeter-
mined. Similarly, levels of didanosine (ddI) were signiﬁ  cantly 
reduced by 20%, and ddI administration several hours prior 
to TPV/r dosing has been advised. Tenofovir levels were 
reduced by 30% which, however, was not signiﬁ  cant and 
therefore no dose adjustment is recommended.
As the NRTIs therapeutic windows are not well-established, 
the clinical relevance of these changes is unknown. Moreover 
the packaging labels for ABC, AZT and ddI do not advise 
alterations in dosage when co-administered with level reducing 
drugs. Therefore a co-administration with ABC or AZT is thus 
so far not recommended unless no other NRTIs are available 
(2005 Boehringer Ingelheim International GmbH; Boehringer 
Ingelheim Pharmaceuticals Inc 2005; Bofﬁ  to, Maitland and 
Pozniak 2006). Similar appropriate doses for the combination 
of TPV/r with APV/r, LPV/r or SQV/r have not been estab-
lished as TPV/r reduces the AUC at steady state for APV/r 
(44%) LPV/r (55%) and SQV/r (76%) (Leith et al 2004). These 
Table 4 Drugs that should not be coadministered with TPV/r
Potential for serious and/or life theatening reactions
Antiarrhythmics Amiodarone
 Bepridil
 Flecainide
 Propafenone
 Qunidine
Antihistamines Astemizole
 Terfenadine
Ergot derviates  Dihydroergotamine
 Ergonovine
 Ergotamine
 Methylergonovine
GI motility agent  Cisapride
Neuroleptic Piomizide
 Sertindole
Sedatives Midazolam
 Triazolam
Risk of sub-therapeutic TPV/r levels 
Antibiotics Rifampicin
Herbal preparations  St John’s Wort 
Increased risk of myopathy, including rhabdomyolysis 
HMG-CoA reductase inhibitors  Lovastatin
 SimvastatinTherapeutics and Clinical Risk Management 2007:3(4) 649
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ﬁ  ndings make a double PI use with TPV/r inadvisable. In 
addition, there is an increased risk of Grade 3/4 elevations in 
hepatic transaminase enzymes if TPV/r is co-administered 
with APV/r. No data are currently available on interactions 
between TPV/r and indinavir, atazanavir, fos-amprenavir or 
nelﬁ  navir. Therefore co-administration of any PI with TPV/r 
is not recommended at this time.
In one drug interaction trial in healthy female volunteers, 
who were administered a single dose of ethinyl estradiol fol-
lowed by TPV/r, more than 50% (n = 29) of subjects (n = 52) 
developed a rash. Rash accompanied by joint pain or stiffness, 
throat tightness, or generalized itching led to discontinuation of 
TPV/r in 20 of the patients. The symptoms were resolved after 
treatment discontinuation. Women taking estrogen-containing 
medications with TPV/r have an increased risk of developing 
a mild to moderate rash and it is associated with a 50% reduc-
tion in ethinyl estradiol levels. This large reduction is below 
the therapeutic window for use of a contraceptive (Boehringer 
Ingelheim GmbH International 2005; 2004 unpublished data 
Boehringer Ingelheim GmbH; Bofﬁ  to 2006).
Discussion
TPV is a protease inhibitor with a unique resistance proﬁ  le 
compared with other protease inhibitors. Based on the exist-
ing data TPV is best used in patients who have failed currently 
available PIs. In RESIST-1 and RESIST-2 tipranavir has 
evidently demonstrated its virological efﬁ  cacy in multiple-PI 
resistant patients. Clearly, overall long-term efﬁ  cacy depends 
on further active components within combination treatment 
including TPV. Enfuvirtide or other active drugs according 
to genotypic resistance testing are ideal partners for treatment 
of patients with PI mutations in whom prior treatment with 
lopinavir or other RTV boosted PIs has failed. Indeed TPV/R 
may have limited efﬁ  cacy when used without enfuvirtide in 
highly drug-experienced patients.
However, the use of TPV in the current HIV treatment 
armamentarium will probably be limited. The RESIST stud-
ies have shown that tipranavir treatment results in a better 
outcome in patients who had used 2 or 3 PIs previously than 
in more experienced patients (Rockstroh, Villacian, Quinson 
et al 2005). But for patients exhibiting less resistance, com-
pared with lopinavir, TPV may offer limited advantage in 
lopinavir sensitive patients, as lopinavir’s side effect proﬁ  le 
seems to be slightly better than for TPV/r and their virological 
efﬁ  cacies were almost identical in this speciﬁ  c patient group. 
In the more advanced treatment population on the other 
hand, several other new protease inhibitors such as darunavir 
(TMC-114) (so far only licensed in the US) and brecanavir 
will become available soon, which are currently in phase 
II-III of development with encouraging in vitro data showing 
good susceptibility as well as results from ﬁ  rst clinical trials 
demonstrating good virological efﬁ  cacy against PI-resistant 
HIV strains (King et al 2004; Koh et al 2003; Katlama et al 
2005; Wilkin et al 2005). Indeed, in the POWER-1 trial in 
patients who were enfurvirtide-naive and received darunavir 
in combination with enfurvirtide 63% of patients achieved 
less than 50 copies/ml at week 24 (n = 19) highlighting the 
antiretroviral potency of the new compound. Moreover, the 
safety proﬁ  le was favorable with no signiﬁ  cant difference 
to the comparator PI arm. However, no studies have yet 
directly compared TMC-114 or brecanavir to tipranavir. In 
addition, large differences in the number of treated patients 
(in the clinical trials) as well as different inclusion criteria 
and baseline resistance proﬁ  les limit the comparison between 
tipranavir and TMC-114 or brecanavir at this time.
As a future scenario it appeared possible that tipranavir might 
also be chosen for treatment of naïve HIV-1 infected patients. 
A study in treatment naïve patients (BI trial 1188.33) receiving 
TPV/r in different dosages (one arm looked at lower ritonavir 
doses for boosting ie, 100 mg RTV bid) however, was recently 
stopped because of increased liver toxicity in the TPV-arm, mak-
ing the earlier use of tipranavir unlikely. Preliminary data from 
another trial for 14 days TPV therapy in treatment inexperienced 
patients had initially demonstrated high efﬁ  cacy, good safety and 
good tolerability by the patients (McCallister et al 2004).
Under consideration of the current trend towards a more 
simpliﬁ  ed and better tolerable ﬁ  rst line regimen, the daily pill 
burden and the tolerability proﬁ  le of TPV make this agent an 
improbable ﬁ  rst choice at present. TPV in the licensed dosing 
is associated with more adverse events and discontinuations 
mostly due to Grade 3 and 4 ALT or triglyceride elevations 
than other boosted PIs. However, the health-related quality 
of life measured by the Medical Outcomes Study-HIV Health 
Survey (MOS-HIV) in patients enrolled in RESIST 1 and 2, 
showed no signiﬁ  cant statistical difference between TPV/r 
and a boosted comparator PI (Woo et al 2005), suggesting 
that most patients adapt to boosted PI/r adverse events.
In conclusion, tipranavir is a new and very potent antiret-
roviral drug, which is an excellent choice for patients, who 
have experience with 2 to 3 PIs; most of these patients’ isolates 
remain sensitive to TPV/r. Preferably, additional, active drugs 
(especially a drug from a class the patient has never received 
before) should be used in a TPV/r containing regimen, which 
as with all other ARV agents, would increase the durability 
of response to TPV/r signiﬁ  cantly. Also TPV/r should be 
considered in salvage therapy as studies showed higher viral Therapeutics and Clinical Risk Management 2007:3(4) 650
Streeck and Rockstroh
load suppression even though the genetic resistance proﬁ  le 
showed several PI primary mutations. Nevertheless, TPV/r 
should be used with caution in patients with underlying hepatic 
impairment under close laboratory observation as the risk for 
development of hepatotoxicity is increased.
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